NIH Just Killed the Payline. Here Is How Grant Decisions Will Actually Work Now.

For thirty years, the unwritten rule of NIH grant applications was brutally simple: score above the payline, get funded. Score below it, try again. The system was imperfect and often frustrating, but it was transparent — researchers could look up their institute's payline, compare it to their study section score, and know roughly where they stood before the official notice arrived.

That system is now gone. In a policy change that has drawn sharp criticism from the research community and cautious praise from some reform advocates, the NIH has directed all 27 institutes and centers to abandon payline-based funding decisions in favor of a multi-factor evaluation process that considers an applicant's career stage, existing funding portfolio, institutional context, and — most controversially — geographic location.

The change arrives at a moment of maximum uncertainty for biomedical researchers. Congress has just set the NIH budget at $48.7 billion for FY2026, a $415 million increase that rejected the White House's proposed 40% cut. But more than half of the agency's 27 institutes now operate under acting directors, and the administration has simultaneously proposed consolidating those institutes from 27 down to 8. The payline change is not happening in a vacuum — it is happening inside an institution that is being reshaped from multiple directions at once.

What Paylines Were and Why They Mattered

NIH paylines were not formal regulations. They were operational thresholds — percentile cutoffs that individual institutes published (or, in some cases, informally communicated) to signal the approximate score needed for an R01 or other investigator-initiated grant to receive funding. The National Institute of General Medical Sciences, for example, might set a payline at the 20th percentile, meaning applications scoring in the top 20% of their study section review would generally be funded.

The system's value was its predictability. Principal investigators could assess their odds, program officers had clear decision criteria, and institutions could plan around expected funding timelines. It was not perfectly meritocratic — study section composition, topic trends, and scoring variance all introduced noise — but it created a shared framework that the research community understood.

Paylines also served as a check on discretionary power. When funding decisions followed a score, program officers had limited ability to steer money toward preferred topics or preferred applicants. The score was the score. That constraint is precisely what the new policy removes.

The New Multi-Factor Model

Under the revised approach, NIH institutes must now weigh several factors beyond the peer-review score when making funding decisions:

Institute priorities. Each institute can identify strategic research areas and preference applications that align with those priorities, even if their scores are not in the top percentile range. This is not entirely new — NIH has always had mechanisms like program announcements and requests for applications to direct funding — but embedding it in every funding decision is a significant expansion.

Career stage. Early-stage investigators and new investigators will receive explicit consideration, potentially receiving funding with scores that would not have cleared the old payline. The NIH has had ESI policies for years, but the new framework makes career stage a factor in all decisions, not just a separate set-aside.

Existing funding. Applicants who already hold substantial NIH funding may face additional scrutiny, with resources potentially redirected toward investigators with fewer active awards. The logic is defensible — the concentration of NIH funding among a relatively small number of well-funded labs has been a documented concern for years. The implementation, however, introduces new judgment calls.

Geographic distribution. This is the factor that has generated the sharpest debate. The new policy explicitly invites institutes to consider an applicant's geographic location — a criterion that critics argue opens the door to political allocation of research funding. Proponents counter that geographic diversity is a legitimate policy goal, noting that NIH funding has historically been concentrated in a handful of coastal states while institutions in the South, Midwest, and Mountain West receive disproportionately less.

Why Researchers Are Alarmed

The concern is not that these factors are irrelevant. Most researchers would agree that career diversity, funding concentration, and geographic equity are real issues worth addressing. The concern is about process.

Under the payline system, a program officer who wanted to fund a lower-scoring application had to make an exception — and exceptions were visible. Under the new system, every funding decision is discretionary by design. There is no default outcome that a score automatically produces. Every award requires a judgment call, and judgment calls can be influenced by factors that have nothing to do with science.

The leadership vacuum compounds the risk. With acting directors running more than half of NIH's institutes, the people making these multi-factor decisions are often temporary appointees who may lack the institutional knowledge — or the institutional independence — to push back against political pressure. An acting director who owes their position to a political appointment has different incentive structures than a Senate-confirmed director with a defined term.

Congress has noticed. The FY2026 appropriations bill includes language requiring NIH to report monthly to Congress on grant awards, terminations, and cancellations — a transparency mechanism that reflects bipartisan concern about politicized funding decisions.

The State-Level Response

The most telling indicator of how the research community perceives these changes is what is happening outside the NIH budget. At least five states have launched or proposed their own biomedical research funding programs — not to replace federal funding, but to insulate researchers from its growing unpredictability.

Massachusetts is considering a $400 million DRIVE initiative (Discovery, Research, and Innovation for a Vibrant Economy) to support university research statewide. Texas voters have already approved $3 billion for dementia research. Pennsylvania Governor Josh Shapiro has proposed $50 million for life sciences. New York is developing the Empire Biomedical Research Institute. California has introduced SB 607 to create a state research fund.

These programs cannot match NIH's scale — state funding has historically comprised less than 1% of total U.S. research spending. But they serve a different function. State grants can provide bridge funding when federal awards are delayed by policy changes, support early-career researchers building NIH-competitive track records, and fund research areas that fall outside shifting federal priorities.

For researchers at institutions in states that are building these programs, the strategic calculus is changing. A state research grant may not carry the prestige of an R01, but it carries certainty — and in a funding environment where the rules are being rewritten mid-game, certainty has real value.

What This Means for Your Next Application

The practical implications for grant seekers depend on where you sit in the research ecosystem.

If you are an early-career investigator: The new system may genuinely help you. ESI consideration was already a factor at most institutes, but elevating it from a separate mechanism to a core decision criterion increases the probability that a strong-but-not-top-scoring application gets funded. Lean into this. Explicitly identify yourself as an ESI in your application, and frame your proposal as building a research program rather than continuing an established one.

If you hold multiple NIH awards: Expect more scrutiny. The policy's emphasis on funding distribution means that multi-R01 investigators may need to make a stronger case for why additional funding is non-duplicative. Consider whether consolidating aims across fewer, larger grants might be strategically preferable to maintaining several smaller ones.

If you are at an institution outside the traditional NIH funding corridor: Geography is now officially a factor. If your institution is in a state or region that has historically been underfunded relative to its research capacity, say so — not as a plea for sympathy, but as a factual statement about the research infrastructure and training opportunities your work supports.

If you are at a well-funded coastal institution: Do not assume that strong scores will automatically translate to funding the way they once did. The removal of paylines means that a 12th-percentile application from a prestigious lab is no longer guaranteed funding if the institute decides to direct resources toward geographic diversity or ESI support. This is not a reason to panic, but it is a reason to diversify your funding strategy — including industry partnerships, foundation grants, and state programs.

For everyone: Watch the institute-level implementation closely. The policy is agency-wide, but each institute will interpret it differently. Some will change very little in practice. Others may use the new flexibility to significantly reshape their funding portfolios. The institutes that publish clear criteria for how they weight the new factors will be the most predictable to apply to. The institutes that do not will be the riskiest.

The NIH's decision to eliminate paylines is the most consequential change to federal research funding policy in a generation. Whether it produces a more equitable, strategically aligned research enterprise or a more politicized, unpredictable one depends entirely on how the 27 institutes choose to exercise their new discretion — and whether anyone is watching closely enough to hold them accountable. Tools like Granted can help researchers track these evolving funding signals across agencies and position their proposals before the new rules fully take effect.